Heron Therapeutics (HRTX) Presents Positive Data from HTX-011 Phase 2 in Hernia Repair

August 29, 2016 8:01 AM EDT
Get Alerts HRTX Hot Sheet
Trade HRTX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that preliminary, positive, top-line results from Heron’s Phase 2 study of HTX-011 in patients undergoing inguinal hernia repair will be presented in two posters at PAINWeek®, the national conference on pain for frontline practitioners, on Thursday, September 8, 2016 in Las Vegas, NV.

Presentation details are as follows:

Poster Title: Local Administration of HTX-011, a Long-Acting Biochronomer-Based Bupivacaine/Meloxicam Combination, in Hernia Repair: Initial Results
Author/Presenter:

Peter J. Winkle, MD, FACP, CPI, FACG, Anaheim Regional Medical Center, Anaheim Clinical Research

Poster Number: 144
Date/Time: Thursday, September 8, 2016 from 6:30 PM – 8:30 PM PT
Location: Level 3, Gracia 7
Poster Title: Local Administration of HTX-011, a Long-Acting Biochronomer-Based Bupivacaine/Meloxicam Combination, in Hernia Repair Provides Similar Initial Results Whether Injected, Instilled, or Both
Author/Presenter: Harold S. Minkowitz, MD, Diplomat American Board of Anesthesiology, Department of Anesthesiology, Memorial Hermann Memorial City Medical Center
Poster Number: 90
Date/Time: Thursday, September 8, 2016 from 6:30 PM – 8:30 PM PT
Location: Level 3, Gracia 7


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment